TMP195 is a selective class IIa HDAC (HDAC4, -5, -7, and -9) inhibitor that has been reported to reprogram tumor-associated macrophages into tumoricidal cells and reduce tumor burden in breast cancer 21. Here, HDAC4 is linked to neoplasm.